Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

PeerView Institute for Medical Education at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

PeerView Institute for Medical Education brings 3 presentations to ASH 2026 in New Orleans. Its program centres on continuing education for hematologists, mainly CAR-T therapy, bispecific antibodies and BTK inhibitors. It supports symposia on lymphoma, myeloma, CLL and mantle cell lymphoma.

OrganizationASH 2026 Attendance
CROs & services
Accredited continuing medical education provider producing live and online programs for clinicians, including hematology and oncology symposia.
Symposium
Fri Dec 11
7:00am–10:00am
Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs
Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity.
Myeloma · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Advancing Bispecific Pathways in ALL: How Clinical Experience and New Science are Informing Off-the-Shelf Innovation
Bispecific T-cell engagers in B-cell acute lymphoblastic leukemia, including gentler next-generation versions for patients unsuited to or relapsing after CAR-T.
Leukemias · New drugs
Symposium
Fri Dec 11
11:00am–2:00pm
Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies
Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse.
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment
Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk.
Lymphoma · New drugs
Symposium
Fri Dec 11
3:00pm–6:00pm
The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care
Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects.
Lymphoma · New drugs
Symposium
Fri Dec 11
7:00pm–10:00pm
Accelerating CARs for Lymphoma: Expert Workshops on CAR-T Standards, Sequencing, and Emerging Cellular Therapy Platforms
CAR-T as standard lymphoma care and what comes next, including dual-target, faster-manufactured, and in vivo versions that could widen patient access.
Lymphoma · Cell & gene

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at PeerView Institute for Medical Education

Tell us what you sell and we’ll find the people at PeerView Institute for Medical Education most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction